{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:41:26Z","timestamp":1782171686731,"version":"3.54.5"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40256-025-00783-4","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T15:44:05Z","timestamp":1767195845000},"page":"283-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Redefining Cardiac Sarcoidosis with Advanced Imaging and Therapeutic Strategies"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-7866","authenticated-orcid":false,"given":"Claudio","family":"Tana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilis","family":"Kouranos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol","family":"Bernardinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Mantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Isra\u00ebl-Biet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"783_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.amjcard.2023.07.123","volume":"204","author":"G Santulli","year":"2023","unstructured":"Santulli G. Cardiac sarcoidosis: updated insights on epidemiology and diagnostic criteria. Am J Cardiol. 2023;204:425\u20137.","journal-title":"Am J Cardiol"},{"issue":"1","key":"783_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00408-015-9805-8","volume":"194","author":"MM Martusewicz-Boros","year":"2016","unstructured":"Martusewicz-Boros MM, Boros PW, Wiatr E, Kempisty A, Piotrowska-Kownacka D, Roszkowski-\u015ali\u017c K. Cardiac sarcoidosis: is it more common in men? Lung. 2016;194(1):61\u20136.","journal-title":"Lung"},{"issue":"18","key":"783_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/heartjnl-2022-322243","volume":"109","author":"T Iso","year":"2023","unstructured":"Iso T, Maeda D, Matsue Y, Dotare T, Sunayama T, Yoshioka K, et al. Sex differences in clinical characteristics and prognosis of patients with cardiac sarcoidosis. Heart. 2023;109(18):1387\u201393.","journal-title":"Heart"},{"issue":"1","key":"783_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/1573405614666180522074320","volume":"15","author":"F Ricci","year":"2019","unstructured":"Ricci F, Mantini C, Grigoratos C, Bianco F, Bucciarelli V, Tana C, et al. The multi-modality cardiac imaging approach to cardiac sarcoidosis. Curr Med Imaging Rev. 2019;15(1):10\u201320.","journal-title":"Curr Med Imaging Rev."},{"issue":"15","key":"783_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/heartjnl-2022-321379","volume":"109","author":"DW Sohn","year":"2023","unstructured":"Sohn DW, Park JB. Cardiac sarcoidosis. Heart. 2023;109(15):1132\u20138.","journal-title":"Heart"},{"key":"783_CR6","doi-asserted-by":"publisher","unstructured":"Tana C, Drent M, Obi ON, Cinetto F, Bernardinello N, Moffa L, et al. Multidisciplinary strategies and new technologies in the management of sarcoidosis. Eur J Intern Med. 2025;106576. https:\/\/doi.org\/10.1016\/j.ejim.2025.106576.","DOI":"10.1016\/j.ejim.2025.106576"},{"issue":"9","key":"783_CR7","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3390\/jcm10091941","volume":"10","author":"C Tana","year":"2021","unstructured":"Tana C, Mantini C, Donatiello I, Mucci L, Tana M, Ricci F, et al. Clinical features and diagnosis of cardiac sarcoidosis. J Clin Med. 2021;10(9):1941.","journal-title":"J Clin Med"},{"key":"#cr-split#-783_CR8.1","doi-asserted-by":"crossref","unstructured":"Miedema J. The immunopathogenesis of sarcoidosis. J Autoimmun. 2024;149:103247","DOI":"10.1016\/j.jaut.2024.103247"},{"key":"#cr-split#-783_CR8.2","doi-asserted-by":"crossref","unstructured":"Spagnolo P, Culver DA. More evidence that sarcoidosis is a host disease, and the identity of the aetiological triggers is irrelevant. Eur Respir J. 2024 Dec 19;64(6):2402051.","DOI":"10.1183\/13993003.02051-2024"},{"issue":"1","key":"783_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175264","volume":"134","author":"P Weeratunga","year":"2024","unstructured":"Weeratunga P, Moller DR, Ho LP. Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis. J Clin Invest. 2024;134(1):e175264.","journal-title":"J Clin Invest"},{"issue":"5","key":"783_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27612","volume":"10","author":"C Chen","year":"2024","unstructured":"Chen C, Luo N. Advances in pathogenesis of sarcoidosis: triggers and progression. Heliyon. 2024;10(5):e27612.","journal-title":"Heliyon"},{"issue":"2","key":"783_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/microorganisms11020289","volume":"11","author":"Y Eishi","year":"2023","unstructured":"Eishi Y. Potential association of cutibacterium acnes with sarcoidosis as an endogenous hypersensitivity infection. Microorganisms. 2023;11(2):289.","journal-title":"Microorganisms"},{"key":"783_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176859","volume":"5;12(5)","author":"D Begh\u00e8","year":"2017","unstructured":"Begh\u00e8 D, Dall\u2019Asta L. Sarcoidosis in an Italian province. Prevalence and environmental risk factors. PLoS ONE. 2017;5;12(5):e0176859.","journal-title":"PLoS ONE"},{"key":"783_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100153","volume":"5","author":"H Bagavant","year":"2022","unstructured":"Bagavant H, Cizio K. Systemic immune response to vimentin and granuloma formation in a model of pulmonary sarcoidosis. J Transl Autoimmun. 2022;5:100153.","journal-title":"J Transl Autoimmun."},{"issue":"21","key":"783_CR14","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1161\/CIR.0000000000001240","volume":"149","author":"RK Cheng","year":"2024","unstructured":"Cheng RK, Kittleson MM, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association. Circulation. 2024;149(21):e1197\u2013216.","journal-title":"Circulation"},{"issue":"17","key":"783_CR15","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/eurheartj\/ehad067","volume":"44","author":"J Lehtonen","year":"2023","unstructured":"Lehtonen J, Uusitalo V. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J. 2023;44(17):1495\u2013510.","journal-title":"Eur Heart J"},{"key":"783_CR16","first-page":"50","volume":"6","author":"E Hulten","year":"2016","unstructured":"Hulten E, Aslam S. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6:50\u201363.","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"783_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ajcp\/aqz169","volume":"153","author":"VD Serei","year":"2020","unstructured":"Serei VD, Fyfe B. The many faces of cardiac sarcoidosis. Am J Clin Pathol. 2020;153:294\u2013302.","journal-title":"Am J Clin Pathol"},{"issue":"16","key":"783_CR18","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.jacc.2020.08.042","volume":"76","author":"MG Trivieri","year":"2020","unstructured":"Trivieri MG, Spagnolo P. Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(16):1878\u2013901.","journal-title":"J Am Coll Cardiol"},{"key":"783_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/hearts2020019","volume":"2","author":"I Pour-Ghaz","year":"2021","unstructured":"Pour-Ghaz I, Kayali S. Cardiac sarcoidosis: pathophysiology, diagnosis, and management. Hearts. 2021;2:234\u201350.","journal-title":"Hearts"},{"issue":"5","key":"783_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.carpath.2010.08.005","volume":"20","author":"JP Veinot","year":"2011","unstructured":"Veinot JP. Endomyocardial biopsy\u2013when and how? Cardiovasc Pathol. 2011;20(5):291\u20136.","journal-title":"Cardiovasc Pathol"},{"key":"783_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0002-8703(99)70115-8","volume":"138","author":"A Uemura","year":"1999","unstructured":"Uemura A, Morimoto S. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138:299\u2013302.","journal-title":"Am Heart J"},{"key":"783_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","volume":"68","author":"DH Birnie","year":"2016","unstructured":"Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68:411\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"783_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/jcm11010251","volume":"11","author":"S Kato","year":"2022","unstructured":"Kato S, Sakai Y. Histology of cardiac sarcoidosis with novel considerations arranged upon a pathologic basis. J Clin Med. 2022;11(1):251.","journal-title":"J Clin Med"},{"issue":"4","key":"783_CR24","doi-asserted-by":"publisher","first-page":"395L","DOI":"10.3390\/diagnostics14040395","volume":"14","author":"D Isra\u00ebl-Biet","year":"2024","unstructured":"Isra\u00ebl-Biet D, Bernardinello N. High-risk sarcoidosis: a focus on pulmonary, cardiac, hepatic and renal advanced diseases, as well as on calcium metabolism abnormalities. Diagnostics (Basel). 2024;14(4):395L.","journal-title":"Diagnostics (Basel)."},{"key":"783_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jce.12401","volume":"25","author":"PB Nery","year":"2014","unstructured":"Nery PB, Beanlands RS. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014;25:875\u201381.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"783_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oead100","volume":"3","author":"Y Fujimoto","year":"2023","unstructured":"Fujimoto Y, Matsue Y. Prevalence and prognostic value of atrial fibrillation in patients with cardiac sarcoidosis. Eur Heart J Open. 2023;3:oead100.","journal-title":"Eur Heart J Open"},{"issue":"2","key":"783_CR27","doi-asserted-by":"publisher","first-page":"26605","DOI":"10.31083\/RCM26605","volume":"26","author":"N Farina","year":"2025","unstructured":"Farina N, De Luca G. Cardiac sarcoidosis: clinical insights, diagnosis, and management strategies. Rev Cardiovasc Med. 2025;26(2):26605.","journal-title":"Rev Cardiovasc Med"},{"key":"783_CR28","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/heartjnl-2019-316442","volume":"107","author":"V Kouranos","year":"2021","unstructured":"Kouranos V, Sharma R. Cardiac sarcoidosis: state-of-the-art review. Heart. 2021;107:1591\u20139.","journal-title":"Heart"},{"issue":"6","key":"783_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061694","volume":"13","author":"D Korthals","year":"2024","unstructured":"Korthals D, Bietenbeck M. Cardiac sarcoidosis-diagnostic and therapeutic challenges. J Clin Med. 2024;13(6):1694.","journal-title":"J Clin Med"},{"key":"783_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2796.2011.02396.x","volume":"270","author":"R Kandolin","year":"2011","unstructured":"Kandolin R, Lehtonen J. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270:461\u20138.","journal-title":"J Intern Med"},{"issue":"345","key":"783_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijcard.2021.10.150","volume":"15","author":"Y Takaya","year":"2021","unstructured":"Takaya Y, Nakamura K. Clinical outcomes of patients with isolated cardiac sarcoidosis confirmed by clinical diagnostic criteria. Int J Cardiol. 2021;15(345):49\u201353.","journal-title":"Int J Cardiol"},{"key":"783_CR32","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s12350-016-0658-1","volume":"25","author":"DR Okad","year":"2018","unstructured":"Okad DR, Bravo PE. Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol. 2018;25:1136\u201346.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"783_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jcmg.2012.10.021","volume":"6","author":"S Greulich","year":"2013","unstructured":"Greulich S, Deluigi CC, Gloekler S, Wahl A, Z\u00fcrn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501\u201311.","journal-title":"JACC Cardiovasc Imaging"},{"key":"783_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000695","author":"Y Khachatoorian","year":"2024","unstructured":"Khachatoorian Y, Fuisz A, Frishman WH, Aronow WS, Ranjan P. The significance of parametric mapping in advanced cardiac imaging. Cardiol Rev. 2024. https:\/\/doi.org\/10.1097\/CRD.0000000000000695. (Epub ahead of print).","journal-title":"Cardiol Rev"},{"issue":"1","key":"783_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/157340561501181207091552","volume":"15","author":"C Tana","year":"2019","unstructured":"Tana C. FDG-PET imaging in sarcoidosis. Curr Med Imaging Rev. 2019;15(1):2\u20133.","journal-title":"Curr Med Imaging Rev"},{"issue":"5","key":"783_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","volume":"21","author":"A Ahmadian","year":"2014","unstructured":"Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al. Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21(5):925\u201339.","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"783_CR37","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00259-007-0650-8","volume":"35","author":"H Ohira","year":"2008","unstructured":"Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35(5):933\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"783_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","volume":"63","author":"R Blankstein","year":"2014","unstructured":"Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63(4):329\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"783_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132780","volume":"10","author":"C Tana","year":"2021","unstructured":"Tana C, Schiavone C. The chameleon behavior of sarcoidosis. J Clin Med. 2021;10(13):2780.","journal-title":"J Clin Med"},{"issue":"6","key":"783_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jcmg.2025.02.010","volume":"18","author":"TS Kafil","year":"2025","unstructured":"Kafil TS, Ribeiro Neto ML, Judson MA, et al. Cardiac Sarcoidosis Expert Panelists. Global practices in cardiac imaging for cardiac sarcoidosis: a survey study of international experts with Delphi consensus. JACC Cardiovasc Imaging. 2025;18(6):679\u201392.","journal-title":"JACC Cardiovasc Imaging"},{"key":"783_CR41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00059-003-2492-x","volume":"28","author":"U Wetzel","year":"2003","unstructured":"Wetzel U, Hindricks G, Dorszewski A, et al. Electroanatomic mapping of the endocardium. Herz. 2003;28:583\u201390.","journal-title":"Herz"},{"issue":"11","key":"783_CR42","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1007\/s40279-018-0985-2","volume":"48","author":"C De Innocentiis","year":"2018","unstructured":"De Innocentiis C, Ricci F, Khanji MY, Aung N, Tana C, Verrengia E, et al. Athlete\u2019s heart: diagnostic challenges and future perspectives. Sports Med. 2018;48(11):2463\u201377.","journal-title":"Sports Med"},{"issue":"6","key":"783_CR43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacep.2020.02.008","volume":"6","author":"JC Hoogendoorn","year":"2020","unstructured":"Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al. Electroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol. 2020;6(6):696\u2013707.","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"783_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10840-018-0410-7","volume":"53","author":"VR Vaidya","year":"2018","unstructured":"Vaidya VR, Abudan AA, Vasudevan K, Shantha G, Cooper LT, Kapa S, et al. The efficacy and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic review. J Interv Card Electrophysiol. 2018;53(1):63\u201371.","journal-title":"J Interv Card Electrophysiol"},{"issue":"5","key":"783_CR45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jchf.2014.03.015","volume":"2","author":"JJ Liang","year":"2014","unstructured":"Liang JJ, Hebl VB, DeSimone CV, Madhavan M, Nanda S, Kapa S, et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail. 2014;2(5):466\u201373.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"783_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCEP.114.002145","volume":"8","author":"S Kumar","year":"2015","unstructured":"Kumar S, Barbhaiya C, Nagashima K, Choi EK, Epstein LM, John RM, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol. 2015;8(1):87\u201393.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2 Pt 1","key":"783_CR47","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0002-8703(99)70115-8","volume":"138","author":"A Uemura","year":"1999","unstructured":"Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138(2 Pt 1):299\u2013302.","journal-title":"Am Heart J"},{"issue":"1","key":"783_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10741-022-10247-5","volume":"28","author":"A Porcari","year":"2023","unstructured":"Porcari A, Baggio C, Fabris E, Merlo M, Bussani R, Perkan A, et al. Endomyocardial biopsy in the clinical context: current indications and challenging scenarios. Heart Fail Rev. 2023;28(1):123\u201335.","journal-title":"Heart Fail Rev"},{"issue":"17","key":"783_CR49","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.107.743427","volume":"118","author":"M Holzmann","year":"2008","unstructured":"Holzmann M, Nicko A, K\u00fchl U, Noutsias M, Poller W, Hoffmann W, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation. 2008;118(17):1722\u20138.","journal-title":"Circulation"},{"issue":"6","key":"783_CR50","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2169\/internalmedicine.9395-17","volume":"57","author":"H Waki","year":"2018","unstructured":"Waki H, Eguchi K. Isolated cardiac sarcoidosis mimicking arrhythmogenic right ventricular cardiomyopathy. Intern Med. 2018;57(6):835\u20139.","journal-title":"Intern Med"},{"issue":"1","key":"783_CR51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJMra1509267","volume":"376","author":"D Corrado","year":"2017","unstructured":"Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(1):61\u201372.","journal-title":"N Engl J Med"},{"key":"783_CR52","first-page":"1533","volume":"121","author":"FI Marcus","year":"2010","unstructured":"Marcus FI, McKenna WJ. Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia. Eur Heart J. 2010;121:1533\u201341.","journal-title":"Eur Heart J"},{"issue":"9","key":"783_CR53","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.hrcr.2017.06.008","volume":"3","author":"R Biggs","year":"2017","unstructured":"Biggs R, Patel B. Cardiac sarcoidosis mimicking arrhythmogenic right ventricular dysplasia in a patient presenting with monomorphic ventricular tachycardia. HeartRhythm Case Rep. 2017;3(9):418\u201321.","journal-title":"HeartRhythm Case Rep."},{"issue":"3","key":"783_CR54","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/ehf2.12725","volume":"7","author":"K Ekstr\u00f6m","year":"2020","unstructured":"Ekstr\u00f6m K, R\u00e4is\u00e4nen-Sokolowski A. Idiopathic giant cell myocarditis or cardiac sarcoidosis? A retrospective audit of a nationwide case series. ESC Heart Fail. 2020;7(3):1362\u201370.","journal-title":"ESC Heart Fail"},{"issue":"26","key":"783_CR55","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJM199706263362603","volume":"336","author":"LT Cooper Jr","year":"1997","unstructured":"Cooper LT Jr, Berry GJ, Multicenter Giant Cell Myocarditis Study Group Investigators. Idiopathic giant-cell myocarditis\u2014natural history and treatment. N Engl J Med. 1997;336(26):1860\u20136.","journal-title":"N Engl J Med"},{"issue":"6","key":"783_CR56","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10741-012-9358-3","volume":"18","author":"LA Blauwet","year":"2013","unstructured":"Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2013;18(6):733\u201346.","journal-title":"Heart Fail Rev"},{"issue":"3","key":"783_CR57","doi-asserted-by":"publisher","first-page":"K25","DOI":"10.1530\/ERP-17-0024","volume":"4","author":"A Cowley","year":"2017","unstructured":"Cowley A, Dobson L. Acute myocarditis secondary to cardiac tuberculosis: a case report. Echo Res Pract. 2017;4(3):K25\u20139.","journal-title":"Echo Res Pract"},{"issue":"1","key":"783_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1573405614666180806141415","volume":"15","author":"O Arar","year":"2019","unstructured":"Arar O, Boni F, Meschi T, Tana C. Pulmonary sarcoidosis presenting with miliary opacities. Curr Med Imaging Rev. 2019;15(1):81\u20133.","journal-title":"Curr Med Imaging Rev"},{"issue":"47","key":"783_CR59","volume":"19","author":"OMP Jolobe","year":"2023","unstructured":"Jolobe OMP. High-risk and low prevalence disease: cardiac sarcoidosis and some of its mimics. Int J Cardiol Heart Vasc. 2023;19(47):101221.","journal-title":"Int J Cardiol Heart Vasc."},{"issue":"7","key":"783_CR60","volume":"15","author":"P Kc","year":"2023","unstructured":"Kc P, Ayele FK, Karki S, Waleed MS. Whipple\u2019s disease mimicking sarcoidosis. Cureus. 2023;15(7):e41839.","journal-title":"Cureus"},{"issue":"1","key":"783_CR61","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12872-019-1257-2","volume":"19","author":"CS Thornton","year":"2019","unstructured":"Thornton CS, Wang Y. Another Whipple\u2019s triad? Pericardial, myocardial and valvular disease in an unusual case presentation from a Canadian perspective. BMC Cardiovasc Disord. 2019;19(1):312.","journal-title":"BMC Cardiovasc Disord"},{"issue":"16","key":"783_CR62","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368.","journal-title":"Eur Heart J"},{"issue":"8","key":"783_CR63","volume":"12","author":"I Ashraf","year":"2020","unstructured":"Ashraf I, Peck MM. Association of arrhythmias in cardiac amyloidosis and cardiac sarcoidosis. Cureus. 2020;12(8):e9842.","journal-title":"Cureus"},{"issue":"2","key":"783_CR64","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ehf2.12263","volume":"5","author":"K Takemura","year":"2018","unstructured":"Takemura K, Nakamura R. A case of cardiac sarcoidosis mimicking cardiac amyloidosis on cardiovascular magnetic resonance. ESC Heart Fail. 2018;5(2):306\u201310.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"783_CR65","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40477-023-00789-1","volume":"26","author":"M Tana","year":"2023","unstructured":"Tana M, Tana C. Imaging findings of right cardiac amyloidosis: impact on prognosis and clinical course. J Ultrasound. 2023;26(3):605\u201314.","journal-title":"J Ultrasound"},{"issue":"10","key":"783_CR66","doi-asserted-by":"publisher","first-page":"291","DOI":"10.31083\/j.rcm2410291","volume":"24","author":"M Tana","year":"2023","unstructured":"Tana M, Tana C. Clinical and cardiovascular magnetic resonance imaging features of cardiac amyloidosis. Rev Cardiovasc Med. 2023;24(10):291.","journal-title":"Rev Cardiovasc Med"},{"issue":"9","key":"783_CR67","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1016\/j.jtha.2024.05.018","volume":"22","author":"M Tana","year":"2024","unstructured":"Tana M, Tana C, Rossi D, Mantini C, Gallina S, Ricci F, et al. Thromboembolic and bleeding risk in cardiac amyloidosis. J Thromb Haemost. 2024;22(9):2381\u201392.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"783_CR68","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","volume":"58","author":"RP Baughman","year":"2021","unstructured":"Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079.","journal-title":"Eur Respir J"},{"issue":"7","key":"783_CR69","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1253\/circj.CJ-14-1275","volume":"79","author":"T Nagai","year":"2015","unstructured":"Nagai T, Nagano N, Sugano Y, Asaumi Y, Aiba T, Kanzaki H, et al. Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis. Circ J. 2015;79(7):1593\u2013600.","journal-title":"Circ J"},{"issue":"5","key":"783_CR70","doi-asserted-by":"publisher","first-page":"2100449","DOI":"10.1183\/13993003.00449-2021","volume":"59","author":"J Stievenart","year":"2022","unstructured":"Stievenart J, Le Guenno G, Ruivard M, Rieu V, Andr\u00e9 M, Grobost V. Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies. Eur Respir J. 2022;59(5):2100449.","journal-title":"Eur Respir J"},{"key":"783_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2024.102082","volume":"43","author":"C Rojulpote","year":"2025","unstructured":"Rojulpote C, Bhattaru A, Patil S, Adams SL, Salas JA, Vidula MK, et al. Assessing the effect of repeat positron emission tomography imaging on treatment response and cardiovascular outcomes among a homogenously treated cohort of patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2025;43:102082.","journal-title":"J Nucl Cardiol"},{"key":"783_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133273","volume":"432","author":"Y Imamura","year":"2025","unstructured":"Imamura Y, Momose M, Yamamoto A, Suzuki A, Serizawa N, Uto K, et al. Long term prognosis in cardiac sarcoidosis under FDG-PET guided immunosuppressive therapy. Int J Cardiol. 2025;432:133273.","journal-title":"Int J Cardiol"},{"issue":"7","key":"783_CR73","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1253\/circj.CJ-14-1422","volume":"79","author":"M Orii","year":"2015","unstructured":"Orii M, Imanishi T, Teraguchi I, Nishiguchi T, Shiono Y, Yamano T, et al. Circulating CD14++CD16+ monocyte subsets as a surrogate marker of the therapeutic effect of corticosteroid therapy in patients with cardiac sarcoidosis. Circ J. 2015;79(7):1585\u201392.","journal-title":"Circ J"},{"issue":"1","key":"783_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeae100","volume":"5","author":"T Segawa","year":"2025","unstructured":"Segawa T, Taniguchi T, Nabeta T, Naruse Y, Kitai T, Yoshioka K, et al. Corticosteroid therapy and long-term outcomes in patients with cardiac sarcoidosis stratified by left ventricular ejection fraction. Eur Heart J Open. 2025;5(1):oeae100.","journal-title":"Eur Heart J Open"},{"key":"783_CR75","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","volume":"132","author":"NA Khan","year":"2017","unstructured":"Khan NA, Donatelli CV, Tonelli AR, Wiesen J, Ribeiro Neto ML, Sahoo D, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med. 2017;132:9\u201314.","journal-title":"Respir Med"},{"issue":"9","key":"783_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098304","volume":"24","author":"C Tana","year":"2023","unstructured":"Tana C, Azorin DG, Cinetto F, Mantini C, Tana M, Caulo M, et al. Common clinical and molecular pathways between migraine and sarcoidosis. Int J Mol Sci. 2023;24(9):8304.","journal-title":"Int J Mol Sci"},{"key":"783_CR77","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","volume":"276","author":"RT Borie","year":"2019","unstructured":"Borie RT, Crestani B, Daugas E, Descamps V, Dieude P, Dossier A, et al. Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs. Int J Cardiol. 2019;276:208\u201311.","journal-title":"Int J Cardiol"},{"issue":"5","key":"783_CR78","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2169\/internalmedicine.53.0794","volume":"53","author":"S Nagai","year":"2014","unstructured":"Nagai S, Yokomatsu T, Tanizawa K, Ikezoe K, Handa T, Ito Y, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med. 2014;53(5):427\u201333.","journal-title":"Intern Med"},{"key":"783_CR79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501443","author":"V Kahlmann","year":"2025","unstructured":"Kahlmann V, Janssen Bon\u00e1s M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk HNAJ, et al. First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2501443. (Epub ahead of print).","journal-title":"N Engl J Med"},{"issue":"4","key":"783_CR80","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s12350-022-03171-6","volume":"30","author":"R Vis","year":"2023","unstructured":"Vis R, Mathijssen H, Keijsers RGM, van de Garde EMW, Veltkamp M, Akdim F, et al. Prednisone vs methotrexate in treatment na\u00efve cardiac sarcoidosis. J Nucl Cardiol. 2023;30(4):1543\u201353.","journal-title":"J Nucl Cardiol"},{"key":"783_CR81","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","volume":"220","author":"D Birnie","year":"2020","unstructured":"Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, et al. Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J. 2020;220:246\u201352.","journal-title":"Am Heart J"},{"key":"783_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108126","volume":"243","author":"P Alipour","year":"2025","unstructured":"Alipour P, Nery PB, Beanlands RS, Wiefels C, Tavoosi A, Boczar K, et al. Durable remission of cardiac sarcoidosis following discontinuation of methotrexate: a prospective cohort study. Respir Med. 2025;243:108126.","journal-title":"Respir Med"},{"issue":"6","key":"783_CR83","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1093\/rheumatology\/keae692","volume":"64","author":"L Brooks","year":"2025","unstructured":"Brooks L, Kivlin W, Mohananey D, Sabchyshyn V, Putman M. Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis. Rheumatology (Oxford). 2025;64(6):3303\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"25","key":"783_CR84","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133\u201340.","journal-title":"Circulation"},{"key":"783_CR85","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2021.02.022","volume":"330","author":"ALM Bakker","year":"2021","unstructured":"Bakker ALM, Mathijssen H, Azzahhafi J, Swaans MJ, Veltkamp M, Keijsers RGM, et al. Effectiveness and safety of infliximab in cardiac Sarcoidosis. Int J Cardiol. 2021;330:179\u201385.","journal-title":"Int J Cardiol"},{"issue":"10","key":"783_CR86","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","volume":"124","author":"LJ Harper","year":"2019","unstructured":"Harper LJ, McCarthy M, Ribeiro Neto ML, Hachamovitch R, Pearson K, Bonanno B, et al. Infliximab for refractory cardiac sarcoidosis. Am J Cardiol. 2019;124(10):1630\u20135.","journal-title":"Am J Cardiol"},{"key":"783_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107004","volume":"203","author":"MA Judson","year":"2022","unstructured":"Judson MA, Adelstein E, Fish KM, Feustel PJ, Yucel R, Preston S, et al. Outcomes of prednisone-tapering regimens for cardiac sarcoidosis: a retrospective analysis demonstrating a benefit of infliximab. Respir Med. 2022;203:107004.","journal-title":"Respir Med"},{"key":"783_CR88","volume":"40","author":"JJG Sweis","year":"2022","unstructured":"Sweis JJG, Sweis NWG, Ascoli C, Levin B, Avitall B, Rubinstein I, et al. Adalimumab in the treatment of cardiac sarcoidosis: single center case series and narrative literature review. Respir Med Case Rep. 2022;40:101766.","journal-title":"Respir Med Case Rep"},{"issue":"18","key":"783_CR89","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010952","volume":"8","author":"P Parwani","year":"2019","unstructured":"DG, Parwani P, Murray TO, Petek BJ, Benn BS, De Marco T, et al. Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc. 2019;8(18):e010952.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"783_CR90","first-page":"218","volume":"23","author":"A Mahmood","year":"2024","unstructured":"Mahmood A, Raja MF, Imran H, Zahoor B, Khan Khakwani MS, Duseja N, et al. TNF alpha inhibitors in cardiac sarcoidosis: a systematic review and meta-analysis. Crit Pathw Cardiol. 2024;23(4):218\u201323.","journal-title":"Crit Pathw Cardiol"},{"issue":"6","key":"783_CR91","doi-asserted-by":"publisher","first-page":"342","DOI":"10.62347\/TSPL4520","volume":"14","author":"LA Hope","year":"2024","unstructured":"Hope LA, Chrusciel T, Abuhaiba B, Verma D, Nayak R, Benjamin MM. Comparison of long-term outcomes in patients with cardiac sarcoidosis treated with different immunosuppressive drugs. Am J Cardiovasc Dis. 2024;14(6):342\u201354.","journal-title":"Am J Cardiovasc Dis"},{"issue":"2","key":"783_CR92","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200429","volume":"15","author":"GS Manzano","year":"2025","unstructured":"Manzano GS, Eaton J, Levy M, Abbatemarco JR, Aksamit AJ, Anand P, et al. Consensus recommendations for the management of neurosarcoidosis: a Delphi survey of experts across the United States. Neurol Clin Pract. 2025;15(2):e200429.","journal-title":"Neurol Clin Pract"},{"issue":"7","key":"783_CR93","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3109\/07853890.2015.1093164","volume":"47","author":"C Tana","year":"2015","unstructured":"Tana C, Wegener S, Borys E, Pambuccian S, Tchernev G, Tana M, et al. Challenges in the diagnosis and treatment of neurosarcoidosis. Ann Med. 2015;47(7):576\u201391.","journal-title":"Ann Med"},{"issue":"19","key":"783_CR94","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030478","volume":"12","author":"C Bueno-Beti","year":"2023","unstructured":"Bueno-Beti C, Lim CX, Protonotarios A, Szabo PL, Westaby J, Mazic M, et al. An mTORC1-dependent mouse model for cardiac sarcoidosis. J Am Heart Assoc. 2023;12(19):e030478.","journal-title":"J Am Heart Assoc"},{"key":"783_CR95","doi-asserted-by":"crossref","unstructured":"Richards D, Fujito H, Shanbhag A, Akhavan B, Frame E, Hayes S, Friedman J, Thomson L, Slomka P, Berman D, Kransdorf EP. Utility of mechanistic target of rapamycin inhibitors in cardiac sarcoidosis. J Card Fail. 2024:S1071-9164(24)00929-1.","DOI":"10.1016\/j.cardfail.2024.10.444"},{"issue":"2","key":"783_CR96","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cardfail.2021.07.008","volume":"28","author":"M Elwazir","year":"2022","unstructured":"Elwazir M, Krause ML, Bois JP, Christopoulos G, Kendi AT, Cooper JLT, et al. Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience. J Card Fail. 2022;28(2):247\u201358.","journal-title":"J Card Fail"},{"key":"783_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.131809","volume":"400","author":"A De Bortoli","year":"2024","unstructured":"De Bortoli A, Nord\u00f8y I, Connelly JP, Viermyr HK, Bjerkreim RH, Broch K, et al. Diagnostics, treatment and outcomes of cardiac sarcoidosis in a Norwegian cohort. Int J Cardiol. 2024;400:131809.","journal-title":"Int J Cardiol"},{"issue":"9","key":"783_CR98","volume":"15","author":"M Venkataraj","year":"2023","unstructured":"Venkataraj M, Pierotti T, Sondhi M, Balmuri S, Hayat S. Novel approach in cardiac sarcoidosis: a case report highlighting abatacept as a promising treatment option. Cureus. 2023;15(9):e45805.","journal-title":"Cureus"},{"issue":"11","key":"783_CR99","first-page":"2167","volume":"42","author":"HCB Leffers","year":"2024","unstructured":"Leffers HCB, Baslund B, Lindhardsen J, Krintel SB, Graudal N. Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response. Clin Exp Rheumatol. 2024;42(11):2167\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"783_CR100","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.123.011869","volume":"16","author":"J Kron","year":"2023","unstructured":"Kron J, Crawford T, Bogun F, Jordan JH, Koelling T, Syed H, et al. Interleukin-1 blockade in cardiac sarcoidosis: a pilot study. Circ Arrhythm Electrophysiol. 2023;16(5):e011869.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"9","key":"783_CR101","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.119.007582","volume":"12","author":"J Kron","year":"2019","unstructured":"Kron J, Mauro AG, Bonaventura A, Toldo S, Salloum FN, Ellenbogen KA, et al. Inflammasome formation in granulomas in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2019;12(9):e007582.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"783_CR102","unstructured":"https:\/\/trial.medpath.com\/clinical-trial\/73ba14a9bdc43e15\/nct06868381-baricitinib-cardiac-sarcoidosis-trial"},{"key":"783_CR103","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017086","volume":"9","author":"W Weng","year":"2020","unstructured":"Weng W, Wiefels C, Chakrabarti S, et al. Atrial arrythmias in clinically manifest cardiac sarcoidosis: incidence, burden, predictors and outcomes. J Am Heart Assoc. 2020;9:e017086.","journal-title":"J Am Heart Assoc"},{"key":"783_CR104","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.120.009203","volume":"14","author":"L Rosenfeld","year":"2021","unstructured":"Rosenfeld L, Chung M, Harding C, et al. Arrythmias in cardiac sarcoidosis bench to bedside: a case-based review. Circ Arrythm Electrophysiol. 2021;14:e009203.","journal-title":"Circ Arrythm Electrophysiol"},{"key":"783_CR105","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCEP.110.959254","volume":"4","author":"R Kandolin","year":"2011","unstructured":"Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as a cause of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4:303\u20139.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"783_CR106","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/ejhf.3057","volume":"25","author":"V Kouranos","year":"2023","unstructured":"Kouranos V, Khattar R, Okafor J, et al. Predictors of outcome in a contemporary cardiac sarcoidosis population: role of brain natriuretic peptide, left ventricular function and myocardial inflammation. Eur J Heart Fail. 2023;25:2287\u201398.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"783_CR107","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jcmg.2016.11.019","volume":"10","author":"V Kouranos","year":"2017","unstructured":"Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging. 2017;10(12):1437\u201347.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"783_CR108","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1378\/chest.07-2784","volume":"133","author":"D Mehta","year":"2008","unstructured":"Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426\u201335.","journal-title":"Chest"},{"issue":"13","key":"783_CR109","first-page":"e272","volume":"138","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272\u2013391.","journal-title":"Circulation"},{"issue":"40","key":"783_CR110","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997\u20134126.","journal-title":"Eur Heart J"},{"issue":"8","key":"783_CR111","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.117.006145","volume":"11","author":"HK Nordenswan","year":"2018","unstructured":"Nordenswan HK, Lehtonen J, Ekstr\u00f6m K, Kandolin R, Simonen P, M\u00e4yr\u00e4np\u00e4\u00e4 M, et al. Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ Arrhythm Electrophysiol. 2018;11(8):e006145.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"24","key":"783_CR112","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025803","volume":"11","author":"S Miyakuni","year":"2022","unstructured":"Miyakuni S, Maeda D, Matsue Y, Yoshioka K, Dotare T, Sunayama T, et al. The prognostic value of b-type natriuretic peptide in patients with cardiac sarcoidosis without heart failure: insights from ILLUMINATE-CS. J Am Heart Assoc. 2022;11(24):e025803.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"783_CR113","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222483","volume":"307","author":"M Aitken","year":"2023","unstructured":"Aitken M, Davidson M, Chan MV, Urzua Fresno C, Vasquez LI, Huo YR, et al. Prognostic value of cardiac MRI and FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Radiology. 2023;307(2):e222483.","journal-title":"Radiology"},{"issue":"30","key":"783_CR114","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/eurheartj\/ehae356","volume":"45","author":"R Sharma","year":"2024","unstructured":"Sharma R, Kouranos V, Cooper LT, Metra M, Ristic A, Heidecker B, et al. Management of cardiac sarcoidosis. Eur Heart J. 2024;45(30):2697\u2013726.","journal-title":"Eur Heart J"},{"issue":"1","key":"783_CR115","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.003738","volume":"9","author":"G Murtagh","year":"2016","unstructured":"Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9(1):e003738.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"783_CR116","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.124.013239","volume":"18","author":"P P\u00f6yh\u00f6nen","year":"2025","unstructured":"P\u00f6yh\u00f6nen P, Lehtonen J, Syv\u00e4ranta S, Velikanova D, M\u00e4lk\u00f6nen H, Simonen P, et al. Magnetic resonance imaging in the assessment of the risk of sudden death in cardiac sarcoidosis: what is extensive or significant late gadolinium enhancement? Circ Arrhythm Electrophysiol. 2025;18(1):e013239.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"8","key":"783_CR117","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s00392-019-01591-y","volume":"109","author":"Y Kagioka","year":"2020","unstructured":"Kagioka Y, Yasuda M, Okune M, Kakehi K, Kawamura T, Kobuke K, et al. Right ventricular involvement is an important prognostic factor and risk stratification tool in suspected cardiac sarcoidosis: analysis by cardiac magnetic resonance imaging. Clin Res Cardiol. 2020;109(8):988\u201398.","journal-title":"Clin Res Cardiol"},{"key":"783_CR118","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2021.11.061","volume":"349","author":"M Adhaduk","year":"2022","unstructured":"Adhaduk M, Paudel B, Liu K, Ashwath M, Giudici M. The role of electrophysiology study in risk stratification of cardiac sarcoidosis patients: meta-analyses and systemic review. Int J Cardiol. 2022;349:55\u201361.","journal-title":"Int J Cardiol"},{"issue":"36","key":"783_CR119","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"2","key":"783_CR120","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10840-020-00705-1","volume":"58","author":"A Halawa","year":"2020","unstructured":"Halawa A, Jain R, Turagam MK, Kusumoto FM, Woldu HG, Gautam S. Outcome of implantable cardioverter defibrillator in cardiac sarcoidosis: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2020;58(2):233\u201342.","journal-title":"J Interv Card Electrophysiol"},{"issue":"5","key":"783_CR121","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/joa3.12753","volume":"38","author":"A Taha","year":"2022","unstructured":"Taha A, Assaf O, Champsi A, Nadarajah R, Patel PA. Outcomes after transvenous defibrillator implantation in cardiac sarcoidosis: a systematic review. J Arrhythm. 2022;38(5):710\u201322.","journal-title":"J Arrhythm"},{"issue":"1","key":"783_CR122","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ehf2.15113","volume":"12","author":"A Liu","year":"2025","unstructured":"Liu A, Ahmed R, Dulay MS, Okafor J, Azzu A, Ramphul K, et al. Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions. ESC Heart Fail. 2025;12(1):592\u2013602.","journal-title":"ESC Heart Fail"},{"issue":"37","key":"783_CR123","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/eurheartj\/ehz428","volume":"40","author":"K Ekstr\u00f6m","year":"2019","unstructured":"Ekstr\u00f6m K, Lehtonen J, Nordenswan HK, M\u00e4yr\u00e4np\u00e4\u00e4 MI, R\u00e4is\u00e4nen-Sokolowski A, Kandolin R, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J. 2019;40(37):3121\u20138.","journal-title":"Eur Heart J"},{"issue":"13","key":"783_CR124","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1161\/CIRCULATIONAHA.121.058120","volume":"146","author":"HK Nordenswan","year":"2022","unstructured":"Nordenswan HK, P\u00f6yh\u00f6nen P, Lehtonen J, Ekstr\u00f6m K, Uusitalo V, Niemel\u00e4 M, et al. Incidence of sudden cardiac death and life-threatening arrhythmias in clinically manifest cardiac sarcoidosis with and without current indications for an implantable cardioverter defibrillator. Circulation. 2022;146(13):964\u201375.","journal-title":"Circulation"},{"issue":"10","key":"783_CR125","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamacardio.2022.2981","volume":"7","author":"PSS Athwal","year":"2022","unstructured":"Athwal PSS, Chhikara S, Ismail MF, Ismail K, Ogugua FM, Kazmirczak F, et al. Cardiovascular magnetic resonance imaging phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis. JAMA Cardiol. 2022;7(10):1057\u201366.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"783_CR126","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jamacardio.2021.4738","volume":"7","author":"KC Siontis","year":"2022","unstructured":"Siontis KC, Santangeli P, Muser D, Marchlinski FE, Zeppenfeld K, Hoogendoorn JC, et al. Outcomes associated with catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. JAMA Cardiol. 2022;7(2):175\u201383.","journal-title":"JAMA Cardiol"},{"key":"783_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","volume":"35","author":"MR Mehra","year":"2016","unstructured":"Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35:1\u201323.","journal-title":"J Heart Lung Transplant"},{"issue":"15","key":"783_CR128","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1161\/CIR.0000000000001016","volume":"144","author":"AA Morris","year":"2021","unstructured":"Morris AA, Khazanie P, Drazner MH, Albert NM, Breathett K, Cooper LB, et al. Guidance for timely and appropriate referral of patients with advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2021;144(15):e238\u201350.","journal-title":"Circulation"},{"key":"783_CR129","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jcmg.2022.11.012","volume":"16","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang J, Hosadurg N, et al. Prognostic value of RV abnormalities on CMR in patients with known or suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2023;16:361\u201372.","journal-title":"JACC Cardiovasc Imaging"},{"key":"783_CR130","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14109","volume":"34","author":"JM Griffin","year":"2020","unstructured":"Griffin JM, DeFilippis EM, Rosenblum H, et al. Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system. Clin Transplant. 2020;34:e14109.","journal-title":"Clin Transplant"},{"issue":"9","key":"783_CR131","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats A, Tsutsui H. Universal definition and classification of heart failure. J Card Fail. 2021;27(9):387\u2013413.","journal-title":"J Card Fail"},{"key":"783_CR132","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/ejhf.1319","volume":"20","author":"LA Fussner","year":"2018","unstructured":"Fussner LA, Karlstedt E, Hodge DO, et al. Management and outcome of cardiac sarcoidosis\u202f: a 20-year experience in two tertiary care centers. Eur J Heart Fail. 2018;20:1713\u201320.","journal-title":"Eur J Heart Fail"},{"key":"783_CR133","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627\u201339.","journal-title":"Eur Heart J"},{"key":"783_CR134","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jchf.2024.02.020","volume":"12","author":"J Ostrominski","year":"2024","unstructured":"Ostrominski J, DeFilippis E, Kannu B, et al. Contemporary American and European Guidelines of heart failure management. JACC Heart Failure. 2024;12:810\u201325.","journal-title":"JACC Heart Failure"},{"key":"783_CR135","first-page":"e876","volume":"145","author":"P Heidenreich","year":"2022","unstructured":"Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: Executive Summary: a report of the American College of Cardiology\/American Heart Association Joint Committee in Clinical Practice Guidelines. Circulation. 2022;145:e876\u201394.","journal-title":"Circulation"},{"key":"783_CR136","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1253\/circj.CJ-24-0205","volume":"89","author":"D Sykora","year":"2025","unstructured":"Sykora D, Bratcher M, Churchill R, et al. Medical therapy and clinical outcomes in cardiac sarcoidosis patients with systolic heart failure. Circ J. 2025;89:41\u201352.","journal-title":"Circ J"},{"key":"783_CR137","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038965","volume":"13","author":"D Sykora","year":"2024","unstructured":"Sykora D, Olson N, Churchill R, et al. Pharmacist medication titration program for patients with cardiac sarcoidosis and systolic heart failure: a retrospective cohort study. J Am Heart Assoc. 2024;13:e038965.","journal-title":"J Am Heart Assoc"},{"key":"783_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2022.12.004","volume":"42","author":"D Saeed","year":"2023","unstructured":"Saeed D, Feldman D, El Banayosy A, et al. The 2023 International Society for heart and lung transplantation guidelines for mechanical circulatory support: a 10-year update. J Heart Lung Transplant. 2023;42:e1-e47.","journal-title":"J Heart Lung Transplant"},{"key":"783_CR139","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2022.01.018","volume":"79","author":"SS Naidu","year":"2022","unstructured":"Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies. J Am Coll Cardiol. 2022;79:933\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"783_CR140","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cardfail.2018.02.009","volume":"24","author":"T Crawford","year":"2018","unstructured":"Crawford T, Okada D, Trent Magruder T, et al. A contemporary analysis of heart transplantation and bridge-to-transplant mechanical circulatory support outcomes in cardiac sarcoidosis. J Card Fail. 2018;24:384\u201391.","journal-title":"J Card Fail"},{"key":"783_CR141","first-page":"978","volume":"34","author":"D Rosenthal","year":"2018","unstructured":"Rosenthal D, Anderson M, Petek B, et al. Invasive hemodynamics and rejection rates in patients with cardiac sarcoidosis after heart transplantation. Can J Cardiol. 2018;34:978\u201382.","journal-title":"Can J Cardiol"},{"key":"783_CR142","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.healun.2021.08.012","volume":"41","author":"KC Jackson","year":"2022","unstructured":"Jackson KC, Youmans QR, Wu T, et al. Heart transplantation outcomes in cardiac sarcoidosis. J Heart Lung Transplant. 2022;41:113\u201322.","journal-title":"J Heart Lung Transplant"},{"key":"783_CR143","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00392-021-01920-0","volume":"111","author":"E Bobbio","year":"2022","unstructured":"Bobbio E, Bj\u00f6rkenstam M, Nwaru B, et al. Short-and long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell myocarditis: a systematic review and meta-analysis. Clin Res Cardiol. 2022;111:125\u201340.","journal-title":"Clin Res Cardiol"},{"key":"783_CR144","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1016\/j.healun.2019.01.733","volume":"38","author":"S Esmaily","year":"2019","unstructured":"Esmaily S, Bobbio E, Bollano E, et al. Inflammatory cardiomyopathy (ICM): long-term survival after heart transplantation or implantation of mechanical circulatory support. J Heart Lung Transplant. 2019;38:S292\u20133.","journal-title":"J Heart Lung Transplant"},{"key":"783_CR145","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.amjcard.2023.08.005","volume":"207","author":"A Stein","year":"2023","unstructured":"Stein A, Stewart B, Patel D, et al. Recurrent cardiac sarcoidosis and giant cell myocarditis after heart transplantation: a case report and systematic literature review. Am J Cardiol. 2023;207:271\u20139.","journal-title":"Am J Cardiol"},{"key":"783_CR146","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"783_CR147","first-page":"478","volume":"16","author":"M Castrichini","year":"2023","unstructured":"Castrichini M, Agboola KM, Vyas H, Abou Ezzeddine OF, Siontis KC, Giudicessi JR, et al. Cardiac sarcoidosis mimickers: genetic testing in undifferentiated inflammatory cardiomyopathies. Circulation. 2023;16(5):478\u20139.","journal-title":"Circulation"},{"issue":"4","key":"783_CR148","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/cells10040766","volume":"10","author":"P S\u00e8ve","year":"2021","unstructured":"S\u00e8ve P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S, et al. Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells. 2021;10(4):766.","journal-title":"Cells"},{"issue":"3","key":"783_CR149","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.itjm.2012.05.002","volume":"6","author":"C Tana","year":"2012","unstructured":"Tana C, Tana M, Mezzetti A, Schiavone C. Sarcoidosis: old certainties and new perspectives. Ital J Med. 2012;6(3):186\u201394.","journal-title":"Ital J Med"},{"issue":"1","key":"783_CR150","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1080\/07853890.2022.2063375","volume":"54","author":"C Tana","year":"2022","unstructured":"Tana C, Drent M, Nunes H, Kouranos V, Cinetto F, Jessurun NT, et al. Comorbidities of sarcoidosis. Ann Med. 2022;54(1):1014\u201335.","journal-title":"Ann Med"},{"issue":"11","key":"783_CR151","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S2213-2600(24)00297-2","volume":"12","author":"M Drent","year":"2024","unstructured":"Drent M, Russell AM, Saketkoo LA, Spagnolo P, Veltkamp M, Wells AU. Representatives of the sarcoidosis community. Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis. Lancet Respir Med. 2024;12(11):848\u201351.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"783_CR152","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2445191","volume":"57","author":"C Tana","year":"2025","unstructured":"Tana C, Bernardinello N, Raffaelli B, Garcia-Azorin D, Waliszewska-Pros\u00f3\u0142 M, Tana M, et al. Neuropsychiatric manifestations of sarcoidosis. Ann Med. 2025;57(1):2445191.","journal-title":"Ann Med"},{"issue":"10","key":"783_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2014.10.009","volume":"25","author":"AA Chokoeva","year":"2014","unstructured":"Chokoeva AA, Tchernev G, Tana M, Tana C. Exclusion criteria for sarcoidosis: a novel approach for an ancient disease? Eur J Intern Med. 2014;25(10):e120.","journal-title":"Eur J Intern Med"},{"issue":"10","key":"783_CR154","first-page":"840","volume":"93","author":"N Soto-Gomez","year":"2016","unstructured":"Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and management of sarcoidosis. Am Fam Physician. 2016;93(10):840\u20138.","journal-title":"Am Fam Physician"},{"issue":"1","key":"783_CR155","doi-asserted-by":"publisher","DOI":"10.1080\/13814788.2024.2418307","volume":"30","author":"M Drent","year":"2024","unstructured":"Drent M, Jans N. Navigating sarcoidosis: recognizing, managing, and supporting patients in primary care. Eur J Gen Pract. 2024;30(1):2418307.","journal-title":"Eur J Gen Pract"},{"issue":"3","key":"783_CR156","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1183\/09031936.06.00105805","volume":"28","author":"JC Grutters","year":"2006","unstructured":"Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J. 2006;28(3):627\u201336.","journal-title":"Eur Respir J"},{"issue":"6736","key":"783_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(52)91525-0","volume":"260","author":"AP Cawadias","year":"1952","unstructured":"Cawadias AP. Internal medicine ad internist. Lancet. 1952;260(6736):683.","journal-title":"Lancet"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00783-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00783-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00783-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:03:07Z","timestamp":1776862987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00783-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":158,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00783-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All figures are original and are not reproduced from another source.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Figures Permissions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Claudio Tana serves as Editor of the Primary Care Section of Annals of Medicine. Vasilis Kouranos, Nicol Bernardinello, Cesare Mantini, Riccardo Scarpa, Francesco Cinetto, Dominique Isra\u00ebl\u2011Biet, and Paolo Spagnolo declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"CT: article concept and design; CT; VK, NB, CM, RS, FC, DIB, PS: article concept and design, collection and\/or assembly of data, writing the article, critical revision of the article, final approval of the article; CT, PS: critical revision of the article, final approval of the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution Statement"}}]}}